In order to provide a plant growth regulator with an excellent plant growth promoting effect, the plant growth regulator of the present invention includes a compound represented by Formula (I) or its tautomer, or an agrochemically acceptable salt thereof.

##STR00001##

where R.sup.1 and R.sup.2 each independently represent a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms, and R.sup.3 to R.sup.5 each independently represent an alkyl group having from 1 to 4 carbon atoms.

Aprotic-protic ionic salt (APS) compositions and methods of using aprotic-protic ionic salt compositions to stabilize nucleic acids at ambient temperatures are provided. Certain aspects provide aprotic-protic ionic salt compositions for long term storage of nucleic acids at ambient temperature in the presence of aqueous solvents.

A non-aqueous electrolyte solution additive, a non-aqueous electrolyte solution for a lithium secondary battery including the same, and a lithium secondary battery including the non-aqueous electrolyte solution are disclosed herein. In some embodiments, the non-aqueous electrolyte solution additive includes a Lewis base compound capable of rapidly reacting with an acid. In some embodiments, the lithium secondary battery including the non-aqueous electrolyte solution has improved high-temperature storage durability.

A non-aqueous electrolyte solution additive, a non-aqueous electrolyte solution for a lithium secondary battery including the same, and a lithium secondary battery including the non-aqueous electrolyte solution are disclosed herein. In some embodiments, the non-aqueous electrolyte solution additive includes a Lewis base compound capable of rapidly reacting with an acid. In some embodiments, the lithium secondary battery including the non-aqueous electrolyte solution has improved high-temperature storage durability.

The application discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, R.sup.1 R.sup.5, R.sup.6 and R.sup.7 are as defined herein.

##STR00001##

The application discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, R.sup.1 R.sup.5, R.sup.6 and R.sup.7 are as defined herein.

##STR00001##

12(S)-hydroxyeicosatrienoic acid (12(S)-HETrE) compounds and compositions comprising the same are disclosed. Methods of using the compounds in the prevention and treatment of thrombosis and thrombotic disorders are also disclosed.

12(S)-hydroxyeicosatrienoic acid (12(S)-HETrE) compounds and compositions comprising the same are disclosed. Methods of using the compounds in the prevention and treatment of thrombosis and thrombotic disorders are also disclosed.

The present disclosure relates to therapeutic agents that may be useful intreatment and prophylaxis of neurodegenerative disorders and/or neural inflammation.

The present invention relates to compounds of formula (I): wherein A, B, L, X, Y, R.sup.1, R.sup.2 and R.sup.4 are as defined in the specification. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP.sub.3.

##STR00001##